Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior has initiated dosing of the first subject in a Phase 2 study of INDV-2000, a non-opioid treatment for Opioid Use Disorder (OUD). This double-blind, placebo-controlled trial will assess the safety and efficacy of INDV-2000 over three months in participants with moderate to severe OUD. Supported by an NIH-HEAL grant, the study aims to determine the dose-response relationship for INDV-2000, an orexin-1 receptor antagonist demonstrated to reduce opioid self-administration in animal studies. INDV-2000 offers a potential new treatment option for individuals seeking non-opioid alternatives.
Indivior, a leading addiction treatment company, will host an analyst teach-in event in New York City, confirming its FY 2024 guidance. The company expects net revenue between $1,240m and $1,330m, an 18% increase from FY 2023. SUBLOCADE revenue is projected at $820m to $880m, a 35% rise. OPVEE revenue is anticipated to be $15m to $25m, and PERSERIS revenue is forecasted at $55m to $65m, a 43% increase. SUBOXONE Film market share is expected to decline by 1-2 percentage points. Adjusted gross margin is estimated to be in the low to mid-80s range.
Adjusted SG&A expenses are projected at $575m to $590m, with R&D expenses between $120m and $130m. Adjusted operating profit is expected to be $330m to $380m. The event will be webcast and aims to provide an in-depth overview of Indivior's growth and value creation strategies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.